The DOI matches its Crossref record; 108 of the 110 references it cites were found in a registry or an index; 25 of the 37 sources its claims cite were checked for support.
Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease
Open accessPublished version of a preprint
Abstract
The incidence of Alzheimer’s disease (AD), the leading cause of dementia, increases rapidly with age, but why age constitutes the main risk factor is still poorly understood. Brain ageing affects oligodendrocytes and the structural integrity of myelin sheaths 1 , the latter of which is associated with secondary neuroinflammation 2,3 . As oligodendrocytes support axonal energy metabolism and neuronal health 4–7 , we hypothesized that loss of myelin integrity could be an upstream risk factor for neuronal amyloid-β (Aβ) deposition, the central neuropathological hallmark of AD. Here we identify genetic pathways of myelin dysfunction and demyelinating injuries as potent drivers of amyloid deposition in mouse models of AD. Mechanistically, myelin dysfunction causes the accumulation of the Aβ-producing machinery within axonal swellings and increases the cleavage of cortical amyloid precursor protein. Suprisingly, AD mice with dysfunctional myelin lack plaque-corralling microglia despite an overall increase in their numbers. Bulk and single-cell transcriptomics of AD mouse models with myelin defects show that there is a concomitant induction of highly similar but distinct disease-associated microglia signatures specific to myelin damage and amyloid plaques, respectively. Despite successful induction, amyloid disease-associated microglia (DAM) that usually clear amyloid plaques are apparently distracted to nearby myelin damage. Our data suggest a working model whereby age-dependent structural defects of myelin promote Aβ plaque formation directly and indirectly and are therefore an upstream AD risk factor. Improving oligodendrocyte health and myelin integrity could be a promising target to delay development and slow progression of AD.
Overview
CoChat Summary
TL;DR
Myelin dysfunction and demyelinating injury act upstream of amyloid-β deposition in mouse models of Alzheimer’s disease, increasing APP processing and altering microglial responses. The authors propose that age-related myelin breakdown is a risk factor for AD by both enhancing Aβ production and distracting microglia from plaques.
Key findings
- Chronic myelin defects increased amyloid plaque load in 6-month-old Cnp−/−;5×FAD and Plp−/y;5×FAD mice, strongest in the hippocampal alveus, but not at 3 months; LSM quantification used n = 8 control and n = 7 mutant mice. Acute demyelination by cuprizone (n = 4 control, n = 5 treated) or EAE (n = 5 per group) also produced small amyloid aggregates in demyelinated regions.
- Myelin dysfunction caused axonal swellings that accumulated APP, BACE1, PSEN2 and Aβ; Cnp−/−;5×FAD mice showed increased BACE1 and cortical APP carboxy-terminal fragments, suggesting enhanced APP processing and Aβ generation.
- Microglia failed to cluster around plaques in Cnp−/−;5×FAD and Plp−/y;5×FAD mice despite increased microglia numbers; bulk RNA-seq (n = 4 per genotype) and snRNA-seq identified distinct myelin-DAM and amyloid-DAM signatures, with amyloid-DAM apparently distracted to myelin damage.
- Forebrain shiverer;5×FAD mice lacking cortical myelin were protected at 3 months but the effect was largely lost by 6 months; they lacked activated microglia/myelin-DAM and axonal swellings or APP metabolism changes.
Methods
- Human autopsy tissue from 3 patients with AD and 3 unaffected individuals was immunostained for CNP, PLP, IBA1 and Me-04 in the medial temporal lobe.
- Mouse models included Cnp−/− and Plp−/y crossbred to 5×FAD or APPNLGF, cuprizone-induced demyelination (0.2% diet for 4 weeks plus 4-week recovery), MOG-induced EAE, and forebrain shiverer (EmxcreMbpfl/fl) mice; analyses used light-sheet microscopy with iDISCO/Congo red, immunofluorescence, EM, western blot, behavioural testing and in vitro phagocytosis.
- Microglia were analysed by MACS bulk RNA-seq (n = 4 per genotype) and snRNA-seq from 6-month-old WT, Cnp−/−, 5×FAD and Cnp−/−;5×FAD mice (two replicates per genotype), plus re-analysis of published human AD snRNA-seq datasets.
Limitations
- Stated: human neuropathology correlations cannot determine whether myelin loss is cause or consequence; the human sample was small (n = 3 per group); cuprizone’s copper-chelating properties interfere with plaque core formation, complicating interpretation; EAE did not produce brain demyelination, so no brain amyloid difference was found; plaque-corralling analysis was not possible in primary demyelination models owing to microglia/macrophage infiltration; further epidemiological studies on MS–AD comorbidity are needed.
- Stated: axonal distress and microgliosis are tightly linked downstream phenomena of myelin injury, making them difficult to study in isolation.
- Evident from the text: the causal evidence comes from mouse models and crossbreeding, not direct human intervention; transcriptomic datasets used limited biological replicates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
14 Valid · 0 Not valid · 5 Not checked · 89 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cluster analysis identified five major microglia and macrophage subpopulations, including two distinct clusters (clusters 4 and 5) with high expression of DAM marker genes37 (Trem2, Lpl and Spp1) (Fig. 5b–d).”
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Myelin defects alter microglia responses
What the sources say
- Partly supportedcites [37] Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290.e17 (2017). sourceExperimental — accuracy not yet measured
The citation is attached to the identification of Trem2, Lpl and Spp1 as DAM marker genes, not to the citing study’s five-cluster analysis. The Results describe increased Trem2 and Lpl expression during the transition to DAM, but the passages found for Spp1 do not identify it as a DAM marker. This source therefore supports only part of the cited marker list. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nearly all have focused on the effect of amyloid plaques and Aβ on oligodendrocytes and myelin, partially describing secondary demyelination or hypomyelination.”
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Ageing myelin as a risk factor for AD
What the sources say
- Partly supportedcites [20] Chen, J.-F. et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer’s disease. Neuron 109, 2292–2307.e5 (2021). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that Aβ deposition causes focal demyelination and changes in oligodendrocyte precursor cells in AD mouse models. It does not establish that nearly all prior studies focused on plaque or Aβ effects, or characterize their findings as secondary hypomyelination. (LLM, conf=0.82)
- Partly supportedcites [21] Zhang, X. et al. Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer’s disease. Sci. Adv. 6, eabb8680 (2020). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes studies in amyloid mouse models linking Aβ accumulation to oligodendrocyte damage and myelin degeneration. It does not establish that nearly all such studies focused on these effects or characterized the myelin changes as secondary demyelination or hypomyelination. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [41] Schmued, L. C., Raymick, J., Paule, M. G., Dumas, M. & Sarkar, S. Characterization of myelin pathology in the hippocampal complex of a transgenic mouse model of Alzheimer’s disease. Curr. Alzheimer Res. 10, 30–37 (2013). source
- Not checked — no full text of the sourcecites [42] Mitew, S. et al. Focal demyelination in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol. 119, 567–577 (2010). source
- Partly supportedcites [43] Behrendt, G. et al. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 61, 273–286 (2013). sourceExperimental — accuracy not yet measured
The Introduction (p. 6) says prior analyses of myelin integrity mainly used the 3xTg AD mouse model, and the paper reports focal demyelination around plaques in APPPS1 mice (p. 11). It does not establish that nearly all earlier studies focused on plaques and Aβ or characterized the changes as secondary demyelination or hypomyelination. The Discussion (p. 16) also notes that myelin abnormalities in 3xTg mice were observed before plaques became visible. (LLM, conf=0.81)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As Ms4a genes can regulate the level of soluble TREM2 and modify AD risk39, we used immunoblot analysis to rule out the possibility that myelin dysfunction affects TREM2 protein levels or cleavage through increased Ms4a expression (Extended Data Fig. 9a).”
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Myelin defects alter microglia responses
What the sources say
- Supportedcites [39] Deming, Y. et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk. Sci. Transl. Med. 11, eaau2291 (2019). source
The citation supports the introductory premise, not the citing authors’ subsequent immunoblot finding about myelin dysfunction. The Discussion states that modulating MS4A4A expression changed extracellular soluble TREM2 and links the MS4A gene region to AD risk; it does not need to establish the citing authors’ own result. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-pressure freezing EM analyses showed that myelin-damage-associated swellings were enriched in vesicular structures that were probably endosomal or lysosomal in origin (Fig. 3a), which are thought to be primary production sites of Aβ32,33.”
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Myelin dysfunction affects APP metabolism
What the sources say
- Partly supportedcites [32] Gowrishankar, S. et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer’s disease amyloid plaques. Proc. Natl Acad. Sci USA. 112, E3699–E3708 (2015). sourceExperimental — accuracy not yet measured
The Abstract and Results report lysosome-like organelles accumulating in swollen axons at Alzheimer’s amyloid plaques. They do not establish that myelin-damage-associated swellings contain these structures, and the cited passages do not describe high-pressure freezing EM of such swellings. (LLM, conf=0.87)
- Partly supportedcites [33] Sadleir, K. R. et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease. Acta Neuropathol. 132, 235–256 (2016). sourceExperimental — accuracy not yet measured
The Fig. 4 caption describes vesicle-filled, dystrophic myelinated axons near amyloid plaques, including one axon that has lost part of its myelin sheath. The Discussion describes possible endosomal and autophagic/lysosomal vesicles. The paper does not establish that myelin damage caused the swellings, and its Electron microscopy methods describe chemical fixation rather than high-pressure freezing. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our imaging data, by contrast, showed an almost complete loss of plaque-corralling microglia, which were previously identified as the in situ equivalent to DAM37.”
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Myelin defects alter microglia responses
What the sources say
- Supportedcites [37] Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290.e17 (2017). source
The citation supports the identification of plaque-associated microglia as the in situ counterpart of DAM, not the citing authors’ own observation of their loss. In the Results, immunostaining and smFISH place DAM-marker-positive microglia near Aβ plaques and identify the DAM population with cells in that location. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
62 more claims · 3 with their cited sources checked
Create a free account to see all 108 claims and every source verdict.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 33
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies of AD pathology have demonstrated that the disease is characterized by the presence of neuritic plaques and neurofibrillary tangles resulting from amyloid-beta (Aβ) accumulation, aggregation of fibrillar plaques, and hyperphosphorylation of tau protein (Depp et al., 2023; Zhang et al., 2023; Kovacs et al., 2024; Wang et al., 2024; Zhang et al., 2025).”
From Multimodal MRI combined with RNA sequencing reveals pathological signatures in the 9-month-old 3×Tg-AD mouse brain (2026) · cites this paper as Depp et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the disruption of myelin homeostasis adversely contributes to many neurological disorders, such as multiple sclerosis, leukodystrophies, and dementia.6,7,8,9,10”
From Neurons sequester the cholesterol-inhibiting TFEB in oligodendrocyte cytoplasm to safeguard myelination and neural function (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The loss of myelin integrity with ageing has been reported to promote Aβ formation and neuronal degeneration in animal models.180”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [180]
The cited source says what the claim attributes to it.
In the citing paper
“myelin alterations have been implicated in AD7–9”
From Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, although oligodendrocyte dysfunction and myelin integrity have been shown to in fl uence A β accumulation 24 , gene expression patterns of oligodendrocyte-enriched transcripts did not differ signi fi cantly amonggenotypes (Fig. 2A).”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [24]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“For cuprizone-mediated demyelination, male 14-week-old 5×FAD mice were fed a powder diet containing 0.2% (w/w) cuprizone (Sigma-Aldrich) for 4 weeks followed by a 4-week recovery period on normal pelleted food without cuprizone supplementation. Control 5×FAD mice received a standard diet without cuprizone. Animals were perfused at 18 weeks of age”
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Methods > Demyelination models
Reported 18 · recomputed 22
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Myelin defects alter microglia responses
“Cluster 4 was almost exclusively derived from cells with the 5×FAD genotype, whereas cluster 5 consisted of cells from the Cnp−/− background (Fig. 5e). We therefore termed these two clusters myelin-DAM and amyloid-DAM, respectively.”
§ Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease > Myelin defects alter microglia responses
“a, Experimental setup for studying microglia states associated with myelin disease (myelin-DAM) and amyloid-disease (amyloid-DAM) and in combination.”
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
UMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Self-citationAlzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2025) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 410
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J.-Z. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 199
“Age-dependent loss of myelin integrity can be a driver or a risk factor of Aβ deposition [183]. β2-microglobulin (β2M), a component of major histocompatibility complex class I (MHC class I), is upregulated in AD brains and constitutes the core of Aβ plaque.”
BackgroundZha, X., Liu, X., Wei, M., Huang, H., Cao, J., Liu, S., Bian, X., Zhang, Y., Xiao, F., Xie, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.006 · Cited by 159
Metadata
- Authors
- Depp, C., Sun, T., Sasmita, A. O., Spieth, L., Berghoff, S. A., Nazarenko, T., Overhoff, K., Steixner-Kumar, A. A., Subramanian, S., Arinrad, S., Ruhwedel, T., Möbius, W., Göbbels, S., Saher, G., Werner, H. B., Damkou, A., Zampar, S., Wirths, O., Thalmann, M., Simons, M., Saito, T., Saido, T., Krueger-Burg, D., Kawaguchi, R., Willem, M., Haass, C., Geschwind, D., Ehrenreich, H., Stassart, R., & Nave, K.-A.
- Affiliations
- Max Planck Institute for Multidisciplinary Sciences (DE)
- German Center for Neurodegenerative Diseases (DE)
- Universitätsmedizin Göttingen (DE)
- University of Göttingen (DE)
- RIKEN Center for Brain Science (JP)
- University of California, Los Angeles (US)
- University Hospital Leipzig (DE)
- Corresponding author
- Depp, Constanze
- Nave, Klaus-Armin
- ORCID
- Depp, Constanze
- Sun, Ting
- Sasmita, Andrew Octavian
- Spieth, Lena
- Berghoff, Stefan A.
- Steixner-Kumar, Agnes A.
- Subramanian, Swati
- Arinrad, Sahab
- Ruhwedel, Torben
- Möbius, Wiebke
- Saher, Gesine
- Werner, Hauke B.
- Damkou, Alkmini
- Zampar, Silvia
- Wirths, Oliver
- Thalmann, Maik
- Simons, Mikael
- Saito, Takashi
- Saido, Takaomi
- Kawaguchi, Riki
- Willem, Michael
- Haass, Christian
- Geschwind, Daniel
- Ehrenreich, Hannelore
- Stassart, Ruth
- Nave, Klaus-Armin
- Venue
- Nature
- Published
- 2023-05-31
- Volume
- 618
- Issue
- 7964
- Pages
- 349-357
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC10247380
- OpenAlex
- W4378909224
- Cited by
- 493
- References
- 110
- Citations by year
- 2026: 157 · 2025: 172 · 2024: 114 · 2023: 41
- FWCI
- 47.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- DZNE Pub (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Funders
- Boehringer Ingelheim Fonds
- Deutsche Forschungsgemeinschaft (TRR-274)
- Max-Planck-Gesellschaft
- Japan Society for the Promotion of Science (23K26790)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, amyloid-beta deposition, oligodendrocytes, demyelination, disease-associated microglia, amyloid plaques, amyloid precursor protein cleavage, axonal swellings, brain aging, single-cell transcriptomics, mouse models of Alzheimer's disease
- MeSH terms
- Single-Cell Gene Expression Analysis, Alzheimer Disease, Animals, Axons, Disease Models, Animal, Myelin Sheath, Risk Factors, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Disease Progression, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41586-023-06120-6
- The paper
- Depp, C., Sun, T., Sasmita, A. O., Spieth, L., Berghoff, S. A., Nazarenko, T., Overhoff, K., Steixner-Kumar, A. A., Subramanian, S., Arinrad, S., Ruhwedel, T., Möbius, W., Göbbels, S., Saher, G., Werner, H. B., Damkou, A., Zampar, S., Wirths, O., Thalmann, M., . . . Nave, K.-A. (2023). Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease. Nature. https://doi.org/10.1038/s41586-023-06120-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.